Vanguard Group Inc. Buys 268,313 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Vanguard Group Inc. lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,565,452 shares of the biopharmaceutical company’s stock after acquiring an additional 268,313 shares during the quarter. Vanguard Group Inc. owned approximately 10.27% of Alnylam Pharmaceuticals worth $6,185,846,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $243,000. Geneos Wealth Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 175 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 34.3% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 1,164 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 297 shares in the last quarter. Nordea Investment Management AB increased its position in shares of Alnylam Pharmaceuticals by 10.4% during the second quarter. Nordea Investment Management AB now owns 11,295 shares of the biopharmaceutical company’s stock valued at $3,640,000 after acquiring an additional 1,060 shares during the last quarter. Finally, Mutual of America Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 16.9% during the second quarter. Mutual of America Capital Management LLC now owns 15,946 shares of the biopharmaceutical company’s stock valued at $5,200,000 after acquiring an additional 2,302 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on ALNY shares. Raymond James Financial reissued an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Chardan Capital cut their price target on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a report on Friday. Wells Fargo & Company lowered their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 20th. Needham & Company LLC dropped their target price on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Finally, Jefferies Financial Group reduced their target price on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research report on Thursday, October 30th. Twenty-two research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $477.38.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $314.40 on Tuesday. The firm has a market capitalization of $41.70 billion, a P/E ratio of 183.86 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The business has a fifty day moving average price of $372.67 and a 200-day moving average price of $424.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The company had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business’s revenue for the quarter was up 84.9% on a year-over-year basis. During the same period last year, the company posted ($0.65) EPS. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the completion of the transaction, the executive vice president directly owned 57,465 shares of the company’s stock, valued at $20,852,324.55. This trade represents a 4.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the company’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total transaction of $848,055.70. Following the completion of the transaction, the executive vice president directly owned 21,264 shares in the company, valued at approximately $7,874,697.12. The trade was a 9.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 19,177 shares of company stock valued at $6,975,746 in the last three months. Insiders own 1.20% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.